Posted by Michael Wonder on 07 Nov 2019
ICER releases draft evidence report on acute migraine therapies
7 November 2019 - Public comment period on preliminary draft now open until 6 December 2019; requests to make oral comment during public meeting also being accepted.
The Institute for Clinical and Economic Review (ICER) today released a Draft Evidence Report assessing the comparative clinical effectiveness and value treatments for acute migraine, including: rimegepant (Biohaven), ubrogepant (Allergan), and lasmiditan (Eli Lilly).
This preliminary draft marks the midpoint of ICER’s eight-month process of assessing these treatments, and the findings within this document should not be interpreted to be ICER’s final conclusions.
